Partnering with Akretiv gives your life science company a financially de-risked access to the Animal Health market (Akretiv investors fund clinical studies and regulatory filing to bring assets to market). You would retain control over IP, development, and manufacturing.

Akretiv offers a flexible deal structure from traditional out-licensing through a fully partnered program to maximize returns for your human life sciences company.

Akretiv’s model provides earlier financial returns (% of upside from program completion deals, sales royalties and supply agreement).

Your human product program could benefit from translational insights from animal studies, early feedback on manufacturing, potentially shortening go-to-market timelines for human therapeutics.

Akretiv gets value from innovative, partially derisked assets for the development of a rich pipeline. Peak financial upside generated at program completion with exit deals (cash at licensing/distribution agreement with strategics and royalties on sales) add to a streamlined cost structure.

Why work with Akretiv?

• Akretiv provides a dedicated team with deep animal health expertise

• Akretiv has relationships with animal health pharmaceutical companies (potential distribution deals, strategic exits)

• Efficient development for funding (including convertible loans model)